Cardiac toxicity of ErbB2-targeted therapies: What do we know?

Clinical Breast Cancer

Volumn 8, Issue SUPPL. 3, 2008, Pages

  Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Brain natriuretic peptide; Lapatinib; Trastuzumab; Troponin I

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; BRAIN NATRIURETIC PEPTIDE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; TRASTUZUMAB; TROPONIN I;

BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; METASTASIS; PATHOPHYSIOLOGY; PATIENT MONITORING; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SOLID TUMOR;

EID: 42449155137     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.s.007     Document Type: Article

References (38)

1. Ainger LE, Bushore J, Johnson WW, et al. Daunomycin: a cardiotoxic agent. J Natl Med Assoc 1971; 63:261-7.
2. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32:302-14.
3. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710-7.
4. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979; 300:278-83.
5. Billingham M, Mason J, Bristow M, et al. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978; 62:865-72.
6. Mackay B, Ewer MS, Carrasco CH, et al. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol 1994; 18:203-11.
7. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23:2900-2.
8. Ewer MS, Vooletich MT, Benjamin RS. A mathematical model for doxorubicin cardiotoxicity: added evidence for the concept of sequential stress. Proc Am Soc Clin Oncol 2004; 23:148 (Abstract 2086).
9. Ewer MS, O'Shaughnessy JA. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer 2007; 7:600-7.
10. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
11. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82.
12. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-12.
13. Chien KR. Herceptin and the heart - a molecular modifier of cardiac failure. N Engl J Med 2006; 354:789-90.
14. Crone SA, Zhao Y-Y, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8:459-65.
15. Ewer MS, Vooletich MT, Durand J-B, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23:7820-6.
16. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20:1215-21.
17. Lemmens K, Fransen P, Sys SU, et al. Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase. Circulation 2004; 109:324-6.
18. Sawyer DB, Zuppinger C, Miller TA, et al. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1β and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 2002; 105:1551-4.
19. Perez EA, Byrne JA, Hammond IW, et al. Results of an analysis of cardiac function in 2,812 patients treated with lapatinib. J Clin Oncol 2006; 24(18 suppl):23s (Abstract 583).
20. Negro A, Brar BK, Lee KF. Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 2004; 59:1-12.
21. HERCEPTIN® [package insert]. South San Francisco, CA: Genentech, Inc.; 2006.
22. Perez EA, Suman VJ, Davidson NE, et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. J Clin Oncol 2005; 23(16 suppl):17s (Abstract 556).
23. Romond EH, Perez EA, Bryant J, et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer. Combined analysis of NSABP-B31/NCCTG-N9831. Presented at: 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL.
24. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study. Available at: http://www.bcirg.org. Accessed: February 1, 2007.
25. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-72.
26. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-84.
27. Bria E, Cuppone F, Former M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat; July 19, 2007 (Epub ahead of print).
28. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007; 25(18 suppl):6s (Abstract 512).
29. Rastogi P, Jeong J, Geyer CE, et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC)→ paclitaxel (T) vs. AC→T with trastuzumab (H). J Clin Oncol 2007; 25(18 suppl):964s (Abstract LBA513).
30. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29-36.
31. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients. Presented at: 29th Annual San Antonio Breast Cancer Symposium; December 14-17. 2006; San Antonio, TX. Abstract 52. Available at: www.abstracts-2view.com/sabcs06/view. php?nu=SABCS06L_78. Accessed: August 15, 2007.
32. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. J Clin Oncol 2008; 26:1231-8.
33. Geyer CE Jr, Bryant JL, Romond EH, et al. Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin, cyclophosphamide (AC)→ paclitaxel (T) vs. AC→T with trastuzumab (H). J Clin Oncol 2006; 24(18 suppl):23s (Abstract 581).
34. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25:3859-65.
35. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer [published correction appears in N Engl J Med 2007; 356:1487]. N Engl J Med 2006; 355:2733-43.
36. Perez EA, Byrne JA, Rappold E, et al. Cardiac safety experience in 3558 patients treated with lapatinib. Annals Oncol 2006; 17(suppl 9):ix70 (Abstract 1420).
37. Storniolo AM, Koehler M, Preston A, et al. Cardiac safety in patients (pts) with metastatic breast cancer (MBC) treated with lapatinib (L) and trastuzumab (TRA). J Clin Oncol 2007; 25(18 suppl):6s (Abstract 514).
38. Kutteh LA, Hobday T, Jaffe A, et al. A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer. J Clin Oncol 2007; 25(18 suppl):22s (Abstract 579).